- Combined nivolumab+ipilimumab is associated with improved treatment-free survival (TFS) compared with either drug alone in patients with advanced melanoma, according to pooled analysis of the CheckMate 067 and 069 trials.
Why this matters
- TFS is a novel outcome measure based on the time between cessation of immune checkpoint inhibitors and initiation of subsequent systemic therapy or death.
- At 36 months, rates of survival free of subsequent therapy initiation were 47% with nivolumab+ipilimumab vs 37% and 15% with nivolumab and ipilimumab alone.
- OS rates were 72%, 69%, and 59%, respectively.
- Nivolumab+ipilimumab was associated with longer restricted mean TFS (11.1 months) than nivolumab alone (4.6 months) or ipilimumab alone (8.7 months).
- Restricted mean TFS without grade 3+ treatment-related adverse events was 10.1, 4.1, and 8.5 months, respectively.
- Pooled data from 1077 patients enrolled in 2 randomized, double-blind trials of nivolumab and ipilimumab.
- TFS analysis was restricted at 36 months.
- Funding: Bristol-Myers Squibb; National Cancer Institute; Yale University; ONO Pharmaceutical Co.
- Different treatment regimens between pooled trials.
- QoL not analyzed.
- Lack of statistical analysis.